Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Juvenile Macular Degeneration Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The market size for juvenile macular degeneration treatment has demonstrated robust growth over recent years. It is projected to expand from $1.28 billion in 2024 to $1.39 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.3%. The expansion observed in the past can be attributed to the increasing prevalence of genetic eye disorders, a rise in investment dedicated to ophthalmic research, an intensified focus on pediatric eye care, the growing prevalence of vision impairment among children, and the accelerating integration of artificial intelligence in eye care diagnostics.
The market for treating juvenile macular degeneration is projected to experience robust expansion over the coming years, anticipated to reach $1.87 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.8%. Factors driving this growth during the forecast period include an expanding elderly demographic, an increase in ophthalmic biotechnology startups, a heightened emphasis on targeted drug delivery systems, a growing volume of clinical trials, and rising investments in gene therapy. Key trends observed within the forecast period encompass progress in genetic testing, the evolution of gene therapies, ongoing stem cell research, regulatory backing for novel treatments, and the adoption of personalized medicine strategies.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23433&type=smp
Which Major Market Drivers Are Shaping The Future Of The Juvenile Macular Degeneration Treatment Market?
The rising occurrence of retinal disorders is anticipated to propel the growth of the juvenile macular degeneration treatment market going forward. Retinal disorders refer to a range of conditions affecting the retina, the light-sensitive layer located at the back of the eye, which can lead to vision impairment or loss. The increase in retinal disorders is linked to the growing prevalence of diabetes, resulting in conditions such as diabetic retinopathy that progressively damage the retina. Juvenile macular degeneration treatments play a crucial role in managing retinal disorders by preserving vision through timely intervention, making them essential for young patients. For instance, in November 2024, a report published by Retina Australia, an Australia-based non-profit organization, stated that approximately 19,000 individuals, or about 1 in 1,380 people, in Australia are estimated to be living with an inherited retinal disease (IRD). Furthermore, the National Eye Institute, a US-based institute of health, projects that the number of Americans with advanced age-related macular degeneration (AMD) will increase from the current 2.1 million to 3.7 million by 2030. Thus, the increasing prevalence of retinal disorders is a key driver for the growth of the juvenile macular degeneration treatment market.
What Are The Key Segments In The Juvenile Macular Degeneration Treatment Market?
The juvenile macular degeneration treatmentmarket covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration; Dry Age-Related Macular Degeneration
2) By Treatment: Devices; Drugs; Surgery
3) By Application: Vision Preservation; Disease Management; Symptom Relief; Preventive Care; Clinical Trials
4) By Sales Channel: Hospitals; Ambulatory Surgical Centres; Other Sales Channel
Subsegments:
1) By Wet Age-Related Macular Degeneration: Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapy; Photodynamic Therapy (PDT); Laser Therapy
2) By Dry Age-Related Macular Degeneration: Nutritional Supplements; Gene Therapy; Stem Cell Therapy
How Are Trends Influencing The Juvenile Macular Degeneration Treatment Market?
Major companies operating in the juvenile macular degeneration treatment market are focusing on developing innovative solutions, such as dual adeno-associated viral (AAV) vectors, to enhance gene therapy delivery and improve treatment efficacy for patients with juvenile macular degeneration. A dual adeno-associated viral (AAV) vector is a gene therapy approach that utilizes two AAV vectors to deliver large therapeutic genes, exceeding the packaging capacity of a single AAV. For instance, in March 2025, SpliceBio, a Spain-based biotechnology company, announced the first patient dosing in its Phase 1/2 ASTRA study for SB-007, a dual AAV vector gene therapy designed to restore full-length ABCA4 protein expression. The therapy aims to provide a potential treatment for juvenile macular degeneration (stargardt disease), an inherited retinal disorder currently without approved treatments, by addressing all patients regardless of their mutations. This milestone marks a significant step toward developing effective gene therapies for rare retinal diseases.
Which Leading Players Are Enhancing Their Juvenile Macular Degeneration Treatment Market Presence Worldwide?
Major companies operating in the juvenile macular degeneration treatment market are F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, AbbVie Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Samsung Bioepis Co. Ltd., Spark Therapeutics Inc., Polpharma Biologics S.A., OrCam Technologies Ltd., Alkeus Pharmaceuticals Inc., Bioeq AG, NuEyes Technologies Inc., Coherus BioSciences Inc., eSight Eyewear Inc., MeiraGTx Holdings plc, Kubota Pharmaceutical Holdings Co. Ltd.
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Juvenile Macular Degeneration Treatment Industry?
North America was the largest region in the juvenile macular degeneration treatment market in 2024. The regions covered in the juvenile macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Juvenile Macular Degeneration Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23433&type=smp
Browse Through More Reports Similar to the Global Juvenile Macular Degeneration Treatment Market 2025, By The Business Research Company
Indexed And Whole Juvenile Life Insurance Global Market Report 2025
Macular Degeneration Treatment Global Market Report 2025
Age Related Macular Degeneration Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model